Screener
BioMarin Pharmaceuticals BMRN Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $989.71M+19.9% | $766.21M+2.8% | $874.57M+17.0% | $776.13M+4.1% | $825.41M+15.9% | ||
| $202.8M+35.1% | $195M+28.7% | $275.71M+103% | $140.09M-25.7% | $150.09M+15.0% | ||
| $786.91M+16.5% | $571.21M-3.8% | $598.86M-2.0% | $636.05M+14.1% | $675.32M+16.1% | ||
| 79.5%-2.3pp | 74.6%-5.1pp | 68.5%-13.3pp | 82%+7.2pp | 81.8%+0.1pp | ||
| $206.95M+28.3% | $178.8M+12.6% | $192.41M+10.9% | $409.48M+121% | $161.31M-12.2% | ||
| $395.55M+70.3% | $258.29M+25.3% | $446.21M+67.4% | $268.42M+5.9% | $232.28M-11.7% | ||
| $878.79M+60.2% | $636.57M+22.1% | $919.18M+56.9% | $822.83M+30.2% | $548.52M-7.3% | ||
| $110.92M-59.9% | $129.64M-42.1% | —— | -$46.69M-141% | $276.89M+130% | ||
| 11.2%-22.3pp | 16.9%-13.1pp | —— | -6%-21.3pp | 33.5%+16.6pp | ||
| $63.3M+2,263% | $14.96M+422% | $2.78M+7.8% | $2.58M-13.1% | $2.68M-25.0% | ||
| $160K-95.2% | $5.37M+324% | —— | —— | $3.37M+242% | ||
| $61.38M-79.4% | $141.2M-40.7% | $0-100% | -$26.32M-120% | $297.87M+125% | ||
| $16.62M-71.0% | $35.68M-31.9% | $19.42M-56.6% | $4.42M-84.4% | $57.34M+130% | ||
| $44.76M-81.4% | $105.53M-43.2% | —— | -$30.74M-129% | $240.53M+124% | ||
| 4.5%-24.6pp | 13.8%-11.1pp | —— | -4%-18.2pp | 29.1%+14.1pp | ||
| $0.23-81.3% | $0.54-43.2% | —— | -$0.16-129% | $1.23+124% | ||
| $208.56M-29.4% | $146.05M-40.6% | $23.22M-87.5% | -$28.21M-121% | $295.45M+101% | ||
| 21.1%-14.7pp | 19.1%-13.9pp | 2.7%-22.1pp | -3.6%-21.5pp | 35.8%+15.2pp | ||
| $110.92M-59.9% | $129.64M-42.1% | $2.78M-98.3% | -$46.69M-141% | $276.89M+130% |
FAQ
- What is BioMarin Pharmaceuticals's revenue?
- BioMarin Pharmaceuticals (BMRN) generated $3.4B in revenue over the trailing twelve months, up 11.2% year over year.
- Is BioMarin Pharmaceuticals profitable?
- BioMarin Pharmaceuticals reported $360.1M in net income over the trailing twelve months, a 16.8% net margin.
- What are BioMarin Pharmaceuticals's profit margins?
- Gross margin is 76.1% and operating margin is 19.9%, with a 16.8% net margin.
- What is BioMarin Pharmaceuticals's earnings per share?
- BioMarin Pharmaceuticals's diluted EPS over the trailing twelve months is $1.84.
- Where does BioMarin Pharmaceuticals's income statement data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
